Breast disease最新文献

{"title":"Clinical significance of Notch receptors in triple negative breast cancer.","authors":"H. Shah, Mittal Mistry, Nupur Patel, H. Vora","doi":"10.21203/rs.3.rs-1305178/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-1305178/v1","url":null,"abstract":"BACKGROUND\u0000The Notch signaling pathway is an evolutionary conserved cell signaling pathway that plays an indispensable role in essential developmental processes. Aberrant activation of Notch pathway is known to initiate wide array of diseases and cancers.\u0000\u0000\u0000OBJECTIVE\u0000To evaluate the clinical significance of Notch receptors in Triple Negative Breast Cancer.\u0000\u0000\u0000METHODS\u0000We evaluated the association between Notch receptors and clinicopathological parameters including disease-free survival and overall survival of one hundred TNBC patients by immunohistochemistry.\u0000\u0000\u0000RESULTS\u0000Positive expression of nuclear Notch1 receptor (18%) was found be significantly correlated with positive lymph node (p = 0.009), high BR score (p = 0.02) and necrosis (p = 0.004) while cytoplasmic expression of Notch2 receptor (26%) was significantly correlated with metastasis (p = 0.05), worse DFS (p = 0.05) and poor OS (p = 0.02) in TNBC patients. Membrane (18%) and cytonuclear (3%) Notch3 expression were significantly associated with poorly differentiated tumors (p = 0.007), high BR score (p = 0.002) and necrosis (p = 0.03) respectively. However, cytoplasmic Notch3 and Notch4 expression were negatively correlated with poor prognostic factors.\u0000\u0000\u0000CONCLUSIONS\u0000Our data indicated that Notch receptors play a key role in promoting TNBC and mainly, Notch2 may contribute to poor prognosis of the disease. Hence, it is implicated that Notch2 may serve as a potential biomarker and therapeutic target for TNBC.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1 1","pages":"85-100"},"PeriodicalIF":0.0,"publicationDate":"2022-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47935654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fibroadenoma of the breast; incidence of malignancy and indicators for surgical intervention: An analysis of 1392 patients.","authors":"Waleed Elnahas,&nbsp;Islam H Metwally,&nbsp;Khaled Bonna,&nbsp;Marco Youssef,&nbsp;Samar AbdAllah,&nbsp;Mohamed Bonna,&nbsp;Mohamed Ali Faried,&nbsp;Mohamed Atef Tira,&nbsp;Omar Hamdy","doi":"10.3233/BD-210074","DOIUrl":"https://doi.org/10.3233/BD-210074","url":null,"abstract":"<p><strong>Background: </strong>Fibroadenomas are common among young females. The size of the lesion used to be an indication for further assessment or excision. With arising of the watch and see proponents, criteria for selecting patients are important to establish.</p><p><strong>Methods: </strong>This is a retrospective study of a prospectively maintained database where all patients having the clinical/radiological provisional diagnosis of fibroadenoma and attending our center - from January 2008 to March 2020 - were enrolled. The primary outcome was the incidence of malignancy and the secondary outcomes were the correlation of malignancy-risk with epidemiologic and radiologic criteria.</p><p><strong>Results: </strong>The study enrolled 1392 patients. The mean age of the patients was 35.7 + ∕- 13.1 years. The median of the longest diameter of the detected breast lesions was 25 mm. The incidence of malignancy was 188 (13.5%). The size of the lesion measured by largest diameter was insignificant (p = 0.99), while the patients' age, marital status, and imaging criteria as measured by BIRADS score were significant (<0.001).</p><p><strong>Conclusion: </strong>Approaching patients with the age above 35 or with BIRADS 4 provisionally diagnosed with fibroadenomas should be cautious with biopsy and short-term follow-ups The size of the tumor alone should not be used as an indication for surgical intervention.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1","pages":"421-426"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10784754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between the expression of Ki67 and histopathological grade, tumor size, disease-free survival, and overall survival among breast cancer patients.","authors":"Radityo Budi Leksono,&nbsp;Rudy Thabry,&nbsp;Prihantono Prihantono,&nbsp;Fritz Nahusuly,&nbsp;Firdaus Kasim,&nbsp;William Hamdani,&nbsp;John Pieter,&nbsp;Indra Indra,&nbsp;Salman Ardi Syamsu,&nbsp;Muhammad Faruk","doi":"10.3233/BD-229005","DOIUrl":"https://doi.org/10.3233/BD-229005","url":null,"abstract":"<p><strong>Introduction: </strong>Identifying Ki67, a monoclonal antibody that recognizes proliferating cells, is important for defining the level of proliferative activity among patients with breast cancer. The purpose of our study was to evaluate the correlation between Ki67's expression and histopathological grade, tumor size, disease-free survival (DFS), and overall survival (OS) among breast cancer patients.</p><p><strong>Methods: </strong>Our retrospective cohort study involved examining 114 patients with breast cancer at our institution from January 2018 to December 2019. Participants were retrospectively followed to determine the progression of their disease, and their 2-year progress was examined with survival analysis, especially regarding whether they had postoperative relapse (i.e., DFS) or had died since being diagnosed (i.e., OS). The data were processed with a chi-square test and Kaplan-Meier test, with significance set at p < 0.05.</p><p><strong>Result: </strong>The overexpression of Ki67 correlated significantly with histopathological grade (p = 0.001), tumor size (p = 0.001), DFS (p = 0.001), and OS (p = 0.003).</p><p><strong>Conclusion: </strong>Ki67's overexpression is significantly correlated with the tumor size, DFS, and OS of patients with breast cancer.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"41 1","pages":"455-460"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10498425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discordance in clinical versus pathological staging in breast cancer: Are we undermining the significance of accurate preoperative staging in the present era?","authors":"Shina Goyal,&nbsp;Linu Abraham Jacob,&nbsp;D Lokanatha,&nbsp;M C Suresh Babu,&nbsp;K N Lokesh,&nbsp;A H Rudresha,&nbsp;Smitha Saldanha,&nbsp;Usha Amirtham,&nbsp;Antony G F Thottian,&nbsp;L K Rajeev","doi":"10.3233/BD-201029","DOIUrl":"https://doi.org/10.3233/BD-201029","url":null,"abstract":"<p><strong>Background: </strong>The present era of individualized treatment for breast cancer is influenced by the initial disease status including the anatomical extent, grade, and receptor status. An accurate preoperative staging is the basis of treatment planning and prognostication. Our study aims to determine the discordance between the preoperative clinical and the postoperative pathological stages of breast cancer patients.</p><p><strong>Methodology: </strong>The medical records of all non-metastatic breast cancer patients from January 2017 to December 2018 who underwent upfront surgery were reviewed. They were staged as per the eighth AJCC and the concordance between the clinical (c) and pathological T (tumor), N (nodal), and final AJCC stage was studied. A Chi-square test was used to determine factors that significantly correlate with disease discordance.</p><p><strong>Results: </strong>A total of 307 breast cancer patients were analyzed. Among these, 43.3% were hormone receptor-positive, 30.6% were Her2 positive and 26% were triple-negative. Overall stage discordance was seen in 48.5% (n = 149) patients (upstaging in 22.1%, downstaging in 26.4%). The discordance rate was 48.9% for T stage (cT versus pT) and 57.4% for N stage (cN versus pN). Among patients with clinically node-negative disease, 53.4% were found to have positive nodes on histopathology, while 27.2% had vice versa. Overall, the factors associated with upstaging were ER-positive, Her2 positive and triple-negative status (all p < 0.05), while none of the factors showed significant association with downstaging.</p><p><strong>Conclusions: </strong>About half of breast cancer patients had discordance between clinical and pathological staging with higher discordance in the nodal stage. This changes the disease prognosis, and may also affect the offered surgical treatment and radiotherapy. Thus highlighting the need for a precise pre-operative staging. Also, this information will aid clinicians in discussions with patients, keeping in mind the likelihood of change in disease staging and management.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" ","pages":"115-121"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39347003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between endocrine resistance and the periods of adjuvant endocrine treatment for hormone receptor-positive, HER2-negative breast cancer.","authors":"Jun Yamamura,&nbsp;Yukiko Miyamura,&nbsp;Shunji Kamigaki,&nbsp;Junya Fujita,&nbsp;Hiroki Osato,&nbsp;Hironobu Manabe,&nbsp;Yumiko Tanaka,&nbsp;Wataru Shinzaki,&nbsp;Yukihiko Hahimot,&nbsp;Toshikazu Ito,&nbsp;Yoshifumi Komoike","doi":"10.3233/BD-210027","DOIUrl":"https://doi.org/10.3233/BD-210027","url":null,"abstract":"<p><strong>Background: </strong>Current guidelines define primary and secondary endocrine resistance according to the periods of adjuvant endocrine therapy (adj-ET); however, the relationship between adj-ET period and endocrine resistance remains unclear.</p><p><strong>Objective: </strong>We examined progression-free survival (PFS) after primary ET for recurrent hormone receptor-positive/HER2-negative breast cancer, and evaluated the relationship between endocrine resistance and the periods of adj-ET.</p><p><strong>Methods: </strong>We assessed PFS among 183 patients who received ET as primary treatment for the first recurrence, according to the period of adj-ET (adj-ET < 1 year, 1-2 years, ≥2 years, and completion).</p><p><strong>Results: </strong>Patients who relapsed during the first year of adj-ET had the significantly shortest PFS. PFS did not significantly differ between patients who relapsed at 1-2 years of adj-ET and patients who relapsed while on adj-ET but after the first 2 years.</p><p><strong>Conclusions: </strong>Relapse at 1-2 years after adj-ET initiation might be better classified as secondary endocrine resistance rather than primary endocrine resistance.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" ","pages":"109-114"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39347006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review and meta-analysis of the papillomavirus prevalence in breast cancer fresh tissues.","authors":"Geilson Gomes de Oliveira,&nbsp;Ana Katherine Gonçalves,&nbsp;José Eleutério,&nbsp;Luiz Gonzaga Porto Pinheiro","doi":"10.3233/BD-201032","DOIUrl":"https://doi.org/10.3233/BD-201032","url":null,"abstract":"<p><strong>Background: </strong>Although widely studied, the role of HPV in the genesis of breast carcinomas remains elusive due to the diversity of results across studies, possibly caused by the wide methodological heterogeneity, some of them with inadequate methods.</p><p><strong>Objective: </strong>To verify the association between HPV and breast cancer through the meta-analysis of studies that used the best-recognized techniques for viral detection and tissue conservation.</p><p><strong>Methods: </strong>A systematic review and meta-analysis restricted to studies that detected HPV by PCR in fresh and frozen tissue from breast cancer were conducted to obtain greater homogeneity. PubMed, Scopus, Science Direct, Cochrane Library, and SciELO were searched until December 14, 2019. Search terms included \"breast cancer\" and \"HPV\" without language restrictions. Eleven studies were included in the meta-analysis. The pooled relative risks and 95% confidence interval (95% CI) were calculated, and heterogeneity was assessed using the I-squared (I2).</p><p><strong>Results: </strong>The selected studies had very low heterogeneity (2%). There is a 2.15 times higher combined relative risk (95% CI = 1.60-2.89) of detecting HPV in breast cancer than in cancer-free breast controls with a statistically significant p-value (p < 0.0001).</p><p><strong>Conclusion: </strong>Our data support the association of DNA-HPV with breast carcinomas. Further studies are needed to find out which breast cancer subtypes this association is most frequent.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" ","pages":"123-132"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39685851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Literature review and case report of bilateral intracystic papillary carcinoma associated with an invasive ductal carcinoma in a male breast.","authors":"Fiona Avau,&nbsp;Marie Chintinne,&nbsp;Sarah Baudry,&nbsp;Frédéric Buxant","doi":"10.3233/BD-210001","DOIUrl":"https://doi.org/10.3233/BD-210001","url":null,"abstract":"<p><p>Intracystic papillary carcinoma (IPC) is a rare tumor with good prognosis that occurs in only 5% to 7.5% of male breast cancer. We report a case of a 46-year-old man who presented a brown nipple discharge a few months ago. He had a bilateral IPC and an invasive ductal carcinoma on the right breast. A double mastectomy was then performed with a bilateral sentinel lymph node biopsy, and he received chemotherapy, radiotherapy, and hormonotherapy. Two years after the diagnosis, the patient recovered and was free of recurrence. Considering the scarcity of this tumor type, we conducted a systematic literature review on the PubMed of all the cases of IPC in men. The clinical presentation, imaging, and treatment of the 43 case reports from the 41 articles selected were described. Furthermore, no clear guidelines for IPC management are available. Conservative surgery should also be preferred, and a sentinel lymph node biopsy should be performed systematically. Moreover, radiotherapy should be proposed in the case of conservative surgery, and hormone therapy could be proposed in the case of invasive IPC or IPC associated with a ductal carcinoma in situ.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" ","pages":"5-13"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3233/BD-210001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39147932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer stem cell population in different molecular subtypes of breast cancer.","authors":"Parul Gupta,&nbsp;Vikram Singh,&nbsp;Sandeep Kumar,&nbsp;Ashim Das,&nbsp;Gurpreet Singh,&nbsp;Amanjit Bal","doi":"10.3233/BD-210050","DOIUrl":"https://doi.org/10.3233/BD-210050","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer heterogeneity is well documented and to some extent is attributed to the presence of cancer stem cells (CSCs). Breast cancer stem cells are identified by the presence of cell surface molecule CD44 and absence of CD24.</p><p><strong>Methods: </strong>In the present study a flowcytometric analysis was done to study the expression distribution of CSC phenotype of CD44+/CD24-/low, among different molecular subtypes of breast cancer and to find a correlation with clinicopathological features.</p><p><strong>Results: </strong>CSCs were observed in all the molecular subtypes of breast cancer. The highest population of CSCs was noted in luminal B (3.4%), followed by TNBC (1.7%), and Her-2 subtype (1.6%). The least number of CD44+/CD24- cells were seen in Luminal A subgroup (1.3%).</p><p><strong>Conclusion: </strong>Existence of cancer stem cells in all the subtypes may suggest the possibility of failure of current therapies in treatment of patients.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" ","pages":"199-203"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39851366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum to: Recent advances in the epidemiology of inflammatory breast cancer.","authors":"Paul H Levine,&nbsp;Carmela C Veneroso","doi":"10.3233/BD-210914","DOIUrl":"https://doi.org/10.3233/BD-210914","url":null,"abstract":"","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" ","pages":"163"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39852665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of MRI in predicting response to neo-adjuvant systemic therapy (NAST) in breast cancer.","authors":"Sadaf Jafferbhoy,&nbsp;Manoj Gowda S,&nbsp;Kirti Katherine Kabeer,&nbsp;Zatinahhayu Mohd-Isa,&nbsp;Seema Salehi-Bird,&nbsp;Sekhar Marla,&nbsp;Sankaran Narayanan,&nbsp;Soni Soumian","doi":"10.3233/BD-210023","DOIUrl":"https://doi.org/10.3233/BD-210023","url":null,"abstract":"<p><strong>Background and objectives: </strong>MRI is generally performed to assess response to Neo-adjuvant systemic therapy (NAST) in breast cancer.</p><p><strong>Objective: </strong>To assess role of MRI in determining the probability of having residual disease in patients undergoing NAST. We also evaluated synchronous cancers diagnosed following MRI.</p><p><strong>Methods: </strong>This is a retrospective study which included all patients who had pre-and post-NAST MRI between June 2014 and December 2019. Data on demographics, tumour characteristics and pathology were collected and analysed. Pre- and post-MRI probability were calculated and depicted on nomograms.</p><p><strong>Results: </strong>The study included 205 patients. Overall pre-MRI probability of having residual disease was 55% (OR:1.2). The post-MRI probability was 78% (95% CI 72-83%; OR:3.5) if MRI showed residual disease and 23% (95% CI 16-31%, OR:0.3) if imaging showed complete response. The absolute benefit was higher in TNBC and HR-HER2. Additional cancers were identified in 8.78% of patients.</p><p><strong>Conclusion: </strong>MRI is beneficial in evaluating response to NAST specifically in TNBC and HR-HER2 cancers. Pre- and post-MRI probabilities of residual disease depicted on nomograms are a useful tool for clinicians. MRI can potentially impact the treatment decisions by identification of synchronous cancers.</p>","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":" ","pages":"165-173"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39962578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}